Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KARS1 | Q15046 | 12/20 | 0.46 |
| ▸ | SYK | P43405 | 4/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.33 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.33 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2225156 | 1.00 | KARS1 (0.46) | KARS1SYKCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2223510 | 0.88 | KARS1 (0.51) | KARS1SYKKCNN1KCNN2KCNN3 | |
| SCHEMBL2223508 | 0.88 | KARS1 (0.51) | KARS1SYKKCNN1KCNN2KCNN3 | |
| SCHEMBL2225286 | 0.86 | KARS1 (0.47) | KARS1SYKKDM4E | |
| SCHEMBL2225285 | 0.86 | KARS1 (0.47) | KARS1SYKKDM4E | |
| SCHEMBL14673949 | 0.83 | KARS1 (0.44) | KARS1SYK | |
| SCHEMBL14673948 | 0.83 | KARS1 (0.44) | KARS1SYK | |
| SCHEMBL14673481 | 0.83 | KARS1 (0.49) | KARS1SYKKCNN1KCNN2KCNN3 | |
| SCHEMBL14673942 | 0.83 | KARS1 (0.52) | KARS1SYKKDM4EHPGD | |
| SCHEMBL2228451 | 0.80 | KARS1 (0.47) | KARS1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2523952-B1 | OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2015-03-04 | — | — | EP | claimed |
| US-8962665-B2 | Thiazole and oxazole kinase inhibitors | AB SCIENCE (FR) | 2015-02-24 | — | — | US | claimed |
| US-20130035331-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2013-02-07 | — | — | US | claimed |
| EP-2523952-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB Science (FR) | 2012-11-21 | — | — | EP | claimed |
| WO-2011086085-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2011-07-21 | — | — | WO | claimed |
| EP-2523952-B1 | OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2015-03-04 | — | — | EP | disclosed |
| US-8962665-B2 | Thiazole and oxazole kinase inhibitors | AB SCIENCE (FR) | 2015-02-24 | — | — | US | disclosed |
| US-8962665-B2 | Thiazole and oxazole kinase inhibitors | AB SCIENCE (FR) | 2015-02-24 | — | — | US | disclosed |
| US-8962665-B2 | Thiazole and oxazole kinase inhibitors | AB SCIENCE (FR) | 2015-02-24 | — | — | US | disclosed |
| US-20130035331-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2013-02-07 | — | — | US | disclosed |
| US-20130035331-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2013-02-07 | — | — | US | disclosed |
| US-20130035331-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2013-02-07 | — | — | US | disclosed |
| EP-2523952-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB Science (FR) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011086085-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | AB SCIENCE (FR) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035331-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | SYK, LTK, MERTK | KARS1 1099/4885SYK 1/4885CYP1A2 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.